hackint0sh/New-Dataset huggingface dataset:
In principle, the present personalized strategy yields the potential to enhance the therapeutic standards achievable with RC alone as well as with single-agent immunotherapy and RC. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Post-hoc biomarker analyses of ongoing phase 2 studies primaryPurpose: OTHER masking: NONE count: 153 type: ESTIMATED name: various neoadjuvant therapies measure: Predictors of immune response to experimental combination therapies in MIBC. measure: Genomic predictors of response to experimental combination therapies in MIBC. measure: Transcriptomic predictors of response to experimental combination therapies in MIBC. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele status: RECRUITING city: Milan state: Mi zip: 20132 country: Italy name: Andrea Necchi, MD role: CONTACT phone: +390226435789 email: necchi.andrea@hsr.it name: Rossella Miotti, PhD role: CONTACT email: miotti.rossella@hsr.it lat: 45.46427 lon: 9.18951 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-02-02 uploadDate: 2024-03-19T18:02 filename: Prot_000.pdf size: 1464434 hasResults: False
nctId: NCT06341465 id: HÜ- FTR- BD- 3 briefTitle: Investigation of the Effects of Exercise and Kinesiological Taping on Spinal Deformities and Serum Markers in Individuals With Scoliosis overallStatus: NOT_YET_RECRUITING date: 2024-04-04 date: 2024-07-04 date: 2024-07-04 date: 2024-04-02 date: 2024-04-02 name: Hacettepe University class: OTHER briefSummary: The aim of this study is to investigate the effects of Schroth exercises and kinesiological taping on spinal deformities and serum markers in young adults with scoliosis. The study will include young adults aged 18-21 with scoliosis. A total of 57 participants will be included in the study. Out of 57 participants, 38 have scoliosis, and 19 are healthy. 38 participants will be randomly divided into 2 groups. One group (n=19) will receive only Schroth exercises, and the other group (n=19) will receive both Schroth exercises and kinesiological taping. The laboratory analyses of proteins associated with autophagy (Beclin-1, LC3, and ATG3) and bone-cartilage metabolism (COMP and MMP-3) will be conducted in the Biomedical Engineering Laboratory of our university. Trunk rotation will be assessed using the Adams Forward Bend Test with scoliometer, quality of life will be evaluated with the SRS-22 Quality of Life questionnaire and Quality of life profile for spinal deformities questionnaire, perception of deformity will be measured using the Walter Reed Visual Assessment Scale, and Cobb angles will be evaluated from anterior-posterior X-ray images. conditions: Scoliosis conditions: Scoliosis Idiopathic conditions: Musculoskeletal Deformity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 3 groups. Schroth exercise group (n=19), schroth exercise and kinesiological taping group (n=19), healthy people (n=19). primaryPurpose: TREATMENT masking: NONE count: 57 type: ESTIMATED name: Just Exercise name: Exercise name: Taping measure: Trunk rotation measure: Cobb angles measure: Serum markers measure: Quality of life with scoliosis people measure: Body image assessment sex: ALL minimumAge: 18 Years maximumAge: 21 Years stdAges: ADULT hasResults: False
nctId: NCT06341452 id: HD-NaM-01-EU briefTitle: Comparison of Individualized Sodium Management Versus Standard Treatment in Hemodialysis acronym: SODIAH overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-03 date: 2025-12 date: 2024-04-02 date: 2024-04-02 name: Fresenius Medical Care Deutschland GmbH class: INDUSTRY briefSummary: The SODIAH study is designed with the aim to assess the impact of isonatremic dialysis on interdialytic weight gain, fluid status, intradialytic hemodynamic stability, and incidence of intradialytic morbid events in dialysis patients. The study will be comparing the Na management option on the 6008 HD dialysis machines with the same machine without the Na management option turned on. Relevant performance and clinical data will be collected as well as information on patients' quality of life and wellbeing. conditions: End Stage Renal Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, open, controlled, parallel, randomized, interventional, multi-center, explorative primaryPurpose: TREATMENT masking: NONE count: 130 type: ESTIMATED name: Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control measure: Interdialytic weight gain measure: Intradialytic hemodynamic stability measure: Intradialytic hemodynamic stability measure: Intradialytic morbid events measure: Fluid status measure: Fluid status measure: PRO: Thirst feeling measure: PRO: Thirst feeling measure: PRO: Fatigue measure: PRO: Hypotensive episodes measure: PRO: HRQOL measure: PRO: Health status sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341439 id: Prot. 001_2023 briefTitle: Clinical Efficacy of Mouthrinses Based on Chlorhexidine 0.12% and CITROX® overallStatus: ACTIVE_NOT_RECRUITING date: 2023-02-18 date: 2024-01-18 date: 2024-03-30 date: 2024-04-02 date: 2024-04-02 name: University of L'Aquila class: OTHER briefSummary: The goal of the following clinical trial is to compare the efficacy of a product based on chlorhexidine 0.12% and CITROX and the same product without CITROX in the healing phenomena that occur after non-surgical periodontal therapy. The main questions it aims to answer are:
Participants, divided into 2 groups, are asked to use either one or the other mouthwash for 14 days after non-surgical periodontal therapy. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: Mouthwash with chlorhexidine 0,12% and CITROX name: Mouthwash with chlorhexidine 0,12% measure: Probing Depth (PD) measure: Gingival Index (GI) measure: Plaque Index (PI) measure: Full mouth plaque score (FMPS) measure: Full mouth bleeding score (FMBS) measure: Patient Reported Outcome Measure (PROMS) sex: ALL minimumAge: 25 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of L'Aquila, division of periodontology city: L'Aquila zip: 67100 country: Italy lat: 42.35055 lon: 13.39954 hasResults: False
nctId: NCT06341413 id: 2023-1281 id: A539500 type: OTHER domain: UW- Madison id: SMPH/SLEEP CENTER/SLEEP CTR type: OTHER domain: UW- Madison id: Protocol version 1/17/2024 type: OTHER domain: UW- Madison id: 1R01MH132221 type: NIH link: https://reporter.nih.gov/quickSearch/1R01MH132221 briefTitle: Sleep and Emotion Processing in Adolescent Post-traumatic Stress Disorder overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2024-10 date: 2024-10 date: 2024-04-02 date: 2024-04-24 name: University of Wisconsin, Madison class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: The goal of this clinical trial is to characterize the role of sleep, emotion processing, and daily affect in post-traumatic stress disorder (PTSD) and whether improving sleep quality using slow wave activity enhancement will impact next-day affect in youth.
* An overnight sleep study following one week of at-home sleep recordings with the device in the sleep enhancement condition conditions: Post Traumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 180 type: ESTIMATED name: SmartSleep device measure: Change in Emotional Regulation - arousal measure: Change in Emotional Regulation - recall measure: Change in Slow-wave Activity (SWA) measure: Change in Positive and Negative Affect Schedule (PANAS) sex: ALL minimumAge: 15 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University of Wisconsin city: Madison state: Wisconsin zip: 53705 country: United States name: Sara Heyn, JD, PhD role: CONTACT phone: 303-296-2116 email: sheyn@wisc.edu name: Stephanie Jones, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06341400 id: 2024-KY-030-01 briefTitle: RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients overallStatus: RECRUITING date: 2024-05-20 date: 2026-05-01 date: 2027-05-01 date: 2024-04-02 date: 2024-04-02 name: Zhujiang Hospital class: OTHER briefSummary: A single-arm, prospective, exploratory clinical trial to explore the pathological complete response (pCR) rate of immune checkpoint inhibitors combined with antibody conjugate drugs as the perioperative treatment of platinum-intolerant bladder cancer patients. Fifty-five patients with clinically or pathologically confirmed muscle-invasive bladder urothelial carcinoma (MIBC) who were ineligible for cisplatin-based chemotherapy or refused cisplatin-based chemotherapy were enrolled. Each subject will receive RC48-ADC and toripalimab intravenously every 2 weeks for a total of 4 cycles before surgery, 8 cycles after surgery. The efficacy was evaluated and followed up after 4 cycles of neoadjuvant therapy, 3 months postoperative, and every 3-6 months thereafter. The primary endpoint of this study was pathological complete response rate (pCR). The secondary endpoints were to explore the safety, disease-free survival (DFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) of RC48 combined with toripalimab neoadjuvant therapy followed by radical cystectomy. conditions: Bladder Cancer conditions: Muscle-Invasive Bladder Carcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 55 type: ESTIMATED name: DisitamabVedotinForIicction Toripalimab measure: PcR sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhujiang Hospital, Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Peng Xu, doctor role: CONTACT phone: 18665073650 lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06341387 id: R178522-ieo1906 briefTitle: Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer overallStatus: RECRUITING date: 2023-05-05 date: 2024-05-30 date: 2024-07-31 date: 2024-04-02 date: 2024-04-02 name: European Institute of Oncology class: OTHER name: University of Rome Tor Vergata briefSummary: The goal of this prospective, case-control study is to discover the specific "omics" biomarkers of early stage of lung cancer using the non-invasive samples (breath, urine and serum) in a total of 200 subjects (100 healthy controls and 100 lung cancer patient). The main questions it aims to answer are:
For each participant we will collected the breath, urine and blood samples. In lung cancer patients group the samples will be sample before lung cancer resection. The samples of Breath, urine and serum will be analysed using different type of analysis: eNose and the Gas Chromatography combined with Ion Mass Spectrometry (GC/IMS). Moreover, Serum will be analyzed by mass-spectrometry-based proteomics. The purpose of these analyses will be to find biomarkers capable of distinguishing the early-stage of lung cancer from the healthy group. Followup will be performed to evaluate the possible change of the volatolomic and proteomic profile. conditions: Lung Cancer conditions: Non-small Cell Lung Cancer Stage I conditions: Non-small Cell Lung Cancer Stage II conditions: Lung Cancer Diagnosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Breath, urine and blood analysis measure: Comparison of the proteomic and volatolomic signature in samples of respiratory exhalation, serum, and urine from patients with lung cancer (stage I/II) and healthy individuals at high risk. measure: Omics-Data intagration. sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Europen insitute of Oncology- Division of Thoracic Surgery status: RECRUITING city: Milan zip: 20141 country: Italy name: Roberto Gasparri, MD, PhD role: CONTACT phone: 0257489499 email: roberto.gasparri@ieo.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06341374 id: 2023/5079 briefTitle: Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients overallStatus: RECRUITING date: 2023-11-06 date: 2024-03-30 date: 2024-09-30 date: 2024-04-02 date: 2024-04-02 name: Parc Taulí Hospital Universitari class: OTHER briefSummary: Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk and dysregulation of immune response in front of infectious agents.
The objective of this study is to evaluate the impact of undiagnosed and non-treated sleep disorders on innate immunity in a cohort of COVID-19 patients and the role of trained immunity induced by influenza vaccination in the innate immune response. conditions: Apnea, Obstructive Sleep conditions: SARS CoV 2 Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Influvac Tetra measure: Immunological study: cytokines. measure: Innate cells: monocytes, classical dendritic cells and Natural Killer cells. measure: Epigenetic modification. measure: Diagnostic of obstructive sleep apnea in selected cohort sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitari Parc Tauli status: RECRUITING city: Sabadell state: Barcelona zip: 08208 country: Spain name: Andrea F Grau, Medicine role: CONTACT phone: +34608151458 email: andreagrau94@gmail.com name: Miguel D Gallego, Medicine role: CONTACT phone: +34616315290 email: mgallego@tauli.cat lat: 41.54329 lon: 2.10942 hasResults: False
nctId: NCT06341361 id: OCT-FFR briefTitle: OCT-based Machine Learning FFR for Predicting Post-PCI FFR overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-04-30 date: 2025-10-15 date: 2024-04-02 date: 2024-04-02 name: Yonsei University class: OTHER name: Gangnam Severance Hospital name: Severance Hospital briefSummary: This study aims to compare the diagnostic accuracy of the fractional flow reserve (FFR) model derived by machine learning based on optical coherence tomography (OCT) exam after coronary artery stent implantation with the wire-based FFR. conditions: Tomography, Optical Coherence conditions: Fractional Flow Reserve, Myocardial studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 82 type: ESTIMATED name: OCT-based machine learning FFR measure: Correlation of OCT-based machine learning FFR compared to wire-based FFR measure: Diagnostic performance of OCT-based machine learning FFR compared to wire-based FFR measure: Diagnostic performance of OCT-based machine learning FFR according to the coronary artery (LAD, LCx or RCA) compared to wire-based FFR sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341348 id: Dalin Tzuchi Hospital briefTitle: Effects of Case Management for Patients With Rheumatoid Arthritis in Taiwan overallStatus: COMPLETED date: 2016-01-01 date: 2018-06-30 date: 2018-12-31 date: 2024-04-02 date: 2024-04-02 name: Dalin Tzu Chi General Hospital class: OTHER briefSummary: Case management (CM) has been recommended as a way of inspiring measurable changes in individual behaviors and improving clinical outcomes for patients with chronic diseases. However, data on its effectiveness for Taiwanese patients with rheumatoid arthritis (RA) are limited. This study aimed to determine the long-term effectiveness of CM that focused on nurses' role among Taiwanese RA patients.
A quasi-experimental pre-post test, control-group study with purposive sampling recruited RA patients from a hospital in Taiwan during 2016-2017. CM program was composed of health education sessions and follow-up telephone consultations over a six-month period. A review of medical records and structured questionnaires yielded data about patient demographics and disease characteristics, and included Chinese version of the Arthritis Self-Efficacy Scale and the Taiwanese Depression Questionnaire. A comparison of the long-term effectiveness of the CM program was made using generalized estimating equation.
This evidence-based study may be beneficial to characterize the long-term effectiveness of CM for Taiwanese patients with RA, and may be a reference for healthcare providers in facilitating the provision of appropriate interventions to improve the adaptation processes and clinical outcomes for them. conditions: Case Management conditions: Rheumatoid Arthritis conditions: Effectiveness studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE maskingDescription: A trained interviewer, who was blind with the study design and participants, was assigned to collect the participants' information on demographic and disease characteristics. count: 96 type: ACTUAL name: Case management measure: Depressive symptoms measure: Self-efficacy level measure: Sexual dysfunctionform-14 measure: DAS28 sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341335 id: AK109-301 briefTitle: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-11 date: 2027-07 date: 2024-04-02 date: 2024-04-02 name: Akeso class: INDUSTRY briefSummary: This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy. conditions: Gastric and Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 506 type: ESTIMATED name: cadonilimab name: pulocimab name: paclitaxel name: placebo measure: Progression-free survival (PFS) assessed by blinded independent central review (BICR) measure: Overall survival (OS) measure: Progression-free survival (PFS) assessed by investigator measure: Objective Response Rate (ORR) measure: Duration of Response (DoR) measure: Disease control rate (DCR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341322 id: ERC0003996 briefTitle: Using Behavioural and Cultural Insights to Increase Colorectal Cancer Home-testing in Croatia overallStatus: RECRUITING date: 2024-03-05 date: 2024-04 date: 2024-07 date: 2024-04-02 date: 2024-04-02 name: Veerle Snijders class: OTHER name: Croatian Institute of Public Health name: Andrija Štampar School of Public Health briefSummary: Colorectal cancer (CRC) is one of the leading causes of death in Croatia. An average of 3600 cases are diagnosed and an average of 2100 people die from the disease every year. Since 2007, Croatia has invited every man and woman aged 50-74 to participate in the home testing screening programme every two years. Currently only around 36% of the invited request the test-kit and 25% complete the home testing procedure, far below the target of 40-60%.
The qualitative component consists of 24 in-depth interviews (IDIs) conducted with members of the target population to identify barriers and drivers to completing colorectal cancer screening home-testing. Data collection for IDIs will be face-to-face, using discussion guides, and will be audio recorded. The audio-recordings will then be analyzed using a rapid analysis approach based on by the modified Capability-Opportunity-Motivation-Behavior (COM-B) framework. conditions: Colorectal Cancer conditions: Behavior Change studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to either control (no reminder screening invitation) or one of three treatments (standard reminder letter, behaviorally informed reminder letter, behaviorally informed letter with home testing kit included). primaryPurpose: SCREENING masking: SINGLE whoMasked: PARTICIPANT count: 13000 type: ESTIMATED name: Standard letter name: Behaviorally informed letter name: Home testing colorectal cancer kit measure: Home test kit ordered measure: Completed colorectal cancer screening measure: Opted out measure: Qualitative feedback sex: ALL minimumAge: 50 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Croatian Institute of Public Health status: RECRUITING city: Zagreb country: Croatia name: Ivana Brkić Biloš, MD role: CONTACT email: ivana.brkic@hzjz.hr name: Nataša Antoljak, Prof role: CONTACT email: natasa.antoljak@hzjz.hr lat: 45.81444 lon: 15.97798 hasResults: False
nctId: NCT06341309 id: CSPC-DEY-CRC-K09 briefTitle: Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-08-01 date: 2024-04-02 date: 2024-04-02 name: West China Hospital class: OTHER briefSummary: To evaluate the progression-free survival (PFS1), objective response rate (ORR), disease control rate (DCR), progression-free survival from first-line treatment initiation (PFS2), overall survival (OS), and safety of irinotecan liposome combined with bevacizumab in patients with advanced metastatic colorectal cancer. conditions: Metastatic Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Irinotecan Liposome name: Bevacizumab measure: Progression free survival -1 measure: Progression free survival -2 measure: Objective response rate measure: Disease control rate measure: Overall survival measure: Incidence of adverse events and severity of adverse events as assessed by CTCAE 5.0 sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341296 id: CSPC-DEY-CRC-K07 briefTitle: Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-12 date: 2024-04-02 date: 2024-04-02 name: West China Hospital class: OTHER briefSummary: To evaluate the objective response rate, disease control rate, progression-free survival, overall survival, surgical conversion rate and safety of irinotecan liposome combined with 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer patients. conditions: Metastatic Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 86 type: ESTIMATED name: Irinotecan Liposome name: 5-FU name: LV name: Bevacizumab measure: Objective response rate measure: Disease control rate measure: Progression free survival measure: Overall survival measure: Percentage of patients undergoing surgery. measure: R0 resection measure: Incidence of adverse events and severity of adverse events as assessed by CTCAE 5.0 sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False